【摘要】 目的 :探讨13 1I 抗CEAMcAb(C5 0 )卵巢癌病人放射免疫显像中血药动力学的特性。方法 :4 3例卵巢癌病人放射免疫显像前后分别测定血清中CEA含量 ,标记抗体循环血液中分布 ,T/NT比值 ,标记抗体放射性半排时间及病人人抗鼠抗体的产生。结果 :标记抗体主要分布于血浆蛋白中 ,13 1I C5 0循环血液中的半清时间平均为 2 3h ,尿中放射性半清时间为 2 4h ,卵巢癌病人在接受标记抗体后 2～ 3周即可产生人抗鼠抗体 ,在体内至少维持 9月以上。结论 :标记抗体血药动力学的研究可指导放射免疫显像的应用 ,抗鼠抗体的产生影响了二次显像效果 ,限制了鼠源性单抗的反复应用更多还原

【Abstract】 Objective: To Probe into the biokinetics of 131 I-Labelled monoclonal antibodies against CEA in 43 ovarian cancer patients who received labelled antibody in diagnostic immunoscintigraphy trials. Method: The CEA in plasma, the distribution and half-life of radio-labeled antibody in circulation and the ratio of T/NT were measured in 28 ovarian cancer patients after radioimmunoscintigraphy. Detection of the anti-mouse-IgG antibody was also conducted. Result: Blood-borne radioactivity was associated predominantly with plasma rather than celluar elements. A bi-phasic decline of radiolabelled antibody ( 131I-C50) was mearured with a half life of 23 hours. Urinary excretion of radioactivity was measured with a half life of 24 hours. Human anti-mouse-IgG antibody (HAMA) was detected 2-3weeks after adminstration of radiolabelled antibody and was present for at least 9 months. Conclusion: The result provides guidance for clinical application of radioimmunoscintigraphy in ovarian cancer, HAMA produces limitations to the efficiency of repeated image studies.更多还原